Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Getting With The PRO-gram: Making Patient-Reported Outcomes Work

Nov 24 2014

• By Kate Rawson

Related Content

<em>Vimizim</em> Panel’s Desire For Quality-Of-Life Data Runs Into Regulatory Reality

Nov 25 2013

FDA Panel Backs Efficacy Of BioMarin’s Rare Disease Drug Vimizim

Nov 20 2013

Related Companies

Genentech, Inc.

Alkermes plc

Bristol Myers Squibb Company

Incyte Corporation

Johnson & Johnson

Novartis AG

BioMarin Pharmaceutical Inc.

Pfizer Inc.

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window